Factors like weight, tolerance, and existing medical conditions impact the dose
doi:10.1016/j.jdiacomp.2020.107733 A Review of Diabetic Gastroparesis for the Community Pharmacist
Preliminary data from a phase 1b extension study (NCT05292911) involving 64 individuals with MRI-PDFF 10% and BMI 28 kg/m 2 demonstrated that 50%, 44%, and 60% of participants presenting baseline alanine aminotransferase (ALT) 30 IU/L reached combined MRI-PDFF reduction 30% and ALT reduction 17 IU/L at pemvidutide doses of 1.2, 1.8, and 2.4 mg, respectively, vs
However, novel formulations have introduced oral tablets as viable administration methods
Journal of Diabetes Investigation, 1(12), 823
Male infertility